LEADER 02315nam  2200613   450 
001 9910789251703321
005 20220503232435.0
010   $a0-12-382031-6
035   $a(CKB)3710000000097669
035   $a(MH)014121363-9
035   $a(SSID)ssj0001184463
035   $a(PQKBManifestationID)12540469
035   $a(PQKBTitleCode)TC0001184463
035   $a(PQKBWorkID)11191784
035   $a(PQKB)11048974
035   $a(Au-PeEL)EBL5754489
035   $a(OCoLC)878805378
035   $a(MiAaPQ)EBC5754489
035   $a(PPN)185198481
035   $a(EXLCZ)993710000000097669
100   $a20190515d2014      uy             0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 14$aThe organic chemistry of drug design and drug action /$fRichard B. Silverman, Mark W. Holladay
205   $aThird edition.
210  1$aAmsterdam :$cElsevier,$d[2014]
210  4$dİ2014
215   $a1 online resource (xviii, 517 pages )$cillustrations (some color)
300   $aBibliographic Level Mode of Issuance: Monograph
311   $a0-12-382030-8 
320   $aIncludes bibliographical references and index.
327   $aIntroduction -- Lead discovery and lead modification -- Receptors -- Enzymes -- Enzyme inhibition and inactivation -- Dna-interactive agents -- Drug resistance and drug synergism -- Drug metabolism -- Prodrugs and drug delivery systems.
606   $aPharmaceutical chemistry
606   $aBioorganic chemistry
606   $aMolecular pharmacology
606   $aDrugs$xDesign
615  0$aPharmaceutical chemistry.
615  0$aBioorganic chemistry.
615  0$aMolecular pharmacology.
615  0$aDrugs$xDesign.
676   $a615.1/9
700   $aSilverman$b Richard B.$013086
702   $aHolladay$b Mark W.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910789251703321
996   $aOrganic chemistry of drug design and drug action$986566
997   $aUNINA
999   $aThis Record contains information from the Harvard Library Bibliographic Dataset, which is provided by the Harvard Library under its Bibliographic Dataset Use Terms and includes data made available by, among others the Library of Congress